| Title |
Patient considerations in the management of ulcerative colitis – role of vedolizumab
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, August 2015
|
| DOI | 10.2147/tcrm.s65650 |
| Pubmed ID | |
| Authors |
Megha Kothari, Prashant Mudireddy, Arun Swaminath |
| Abstract |
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6-24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn's disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific focus on the management of UC. Additionally, data on safety and the current UC management protocols are also discussed. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Qatar | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 75% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 20% |
| Student > Master | 6 | 12% |
| Other | 4 | 8% |
| Student > Ph. D. Student | 4 | 8% |
| Student > Bachelor | 3 | 6% |
| Other | 13 | 25% |
| Unknown | 11 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 41% |
| Psychology | 3 | 6% |
| Computer Science | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 11 | 22% |
| Unknown | 10 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2015.
All research outputs
#14,600,553
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#611
of 1,323 outputs
Outputs of similar age
#126,556
of 276,431 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#20
of 49 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,431 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.